NCT04714372 2024-10-24
FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
Masonic Cancer Center, University of Minnesota
Eli Lilly and Company
Therapeutic Advances in Childhood Leukemia Consortium
University of Florida
Eli Lilly and Company